RNaseH2 inhibition potentiates temozolomide response in patient derived glioblastoma cells

Abstract Glioblastoma (GBM) is the most common and lethal form of primary brain tumor, characterized by poor prognosis and limited treatment options, with a median survival of only 12 to 15 months post-diagnosis. Despite standard therapeutic protocols involving temozolomide (TMZ) and radiotherapy, e...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Miroslava Kissova, Judit Martinez Segarra, Tobias Solli Iveland, Marthe Vestvik, Erlend Ravlo, Wei Wang, Lars Hagen, Nina-Beate Liabakk, Maria Camara-Quilez, Miquel Arano Barenys, Ole Solheim, Bård Helge Hoff, Eirik Sundby, Magnar Bjørås, Geir Slupphaug, Torkild Visnes, Alessandro Brambilla
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Nature Portfolio 2025-11-01
Σειρά:	Scientific Reports
Θέματα:	GBM High-throughput screening (HTS) Drug screening
Διαθέσιμο Online:	https://doi.org/10.1038/s41598-025-25298-5
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!